Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038167 · ClinicalTrials.gov registry record · Phase 1
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
A Phase 1 study of Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01038167: Completed Phase 1 study of Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated.
NCT01038167 is a Phase 1 study of Hepatitis C that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 20 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01038167, a Phase 1 study of Hepatitis C, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect that telaprevir has on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.
Conditions Studied
Interventions
- DRUG tacrolimus
- DRUG cyclosporine
- DRUG telaprevir
Study Locations (1)
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
What the finished NCT01038167 record still lists
NCT01038167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which tacrolimus is the first listed.
NCT01038167 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01038167 about?
NCT01038167 is a clinical study titled "A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults". The purpose of this study is to evaluate the effect that telaprevir has on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.
What is the current status of trial NCT01038167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-01. Estimated completion is 2010-04.
What conditions does trial NCT01038167 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01038167?
The interventions under investigation include: tacrolimus (DRUG), cyclosporine (DRUG), telaprevir (DRUG).
Who is sponsoring clinical trial NCT01038167?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01038167 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01038167's enrollment target sits among peer trials
20 94th of 106 higher than 9 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia